How Much Does Xarelto Cost in 2026?

Xarelto (rivaroxaban) is a once-daily blood thinner used to prevent stroke in atrial fibrillation and to treat and prevent blood clots. Medicare negotiated $197 for a 30-day supply, 62% below the $517 list price, effective January 1, 2026. Two things to know: it is lower than Eliquis at $231, and because generic competition now exists CMS is removing Xarelto from the negotiation program on January 1, 2027.

  • Medicare's negotiated price is $197 per 30-day supply for 2026 only. Xarelto exits the negotiation program on January 1, 2027, after which your plan sets the price the ordinary way.
  • It is cheaper than Eliquis at the Medicare level, $197 against $231, but that is not the same as cheaper for you, because your copay depends on your plan's tier for each drug.
  • CMS removed Xarelto because it determined bona fide generic competition now exists. FDA-approved generic rivaroxaban exists, though availability has been uneven across the different tablet strengths.
  • Do not switch anticoagulants on price. These drugs prevent strokes, the dosing differs, and the choice belongs with your prescriber.

What You Actually Pay

Figures are for a 30-day supply. List and negotiated prices are from CMS; what you pay depends on your coverage.

Your situationTypical cost
Medicare negotiated price, 2026$197 / 30 days
Medicare Part D, your shareup to $2,100 / year
Commercial insurancecopay or coinsurance
Uninsured, cash~$517 (list)

Xarelto Is Leaving the Program, and Why That Is Not Bad News

Medicare can only negotiate a drug that faces no bona fide generic competition. Xarelto met that test when it was selected, but the picture changed: key patents lapsed, the FDA approved generic rivaroxaban, and CMS determined real competition now exists. The consequence is that Xarelto, along with Entresto and Stelara, stops being a selected drug on January 1, 2027, and the $197 negotiated price applies for 2026 only.

That is usually an improvement rather than a loss, because generic competition tends to drive prices well below any negotiated figure. The practical caution is about availability rather than price: generic rivaroxaban launched unevenly across the 2.5 mg, 10 mg, 15 mg and 20 mg strengths, and the 15 mg and 20 mg doses are the ones most people with atrial fibrillation take. So ask your pharmacist specifically whether a generic exists at your dose, rather than whether a generic exists at all.

What Medicare's Negotiated Price Does, and Does Not, Change

The headline number is not your copay.

$197 is the maximum fair price, the amount Medicare and your Part D plan pay for a 30-day supply of Xarelto. What you are charged at the counter is still set by your plan's tier and cost-sharing rules.

It helps you directly if you pay coinsurance

Many plans charge a percentage of the drug's price on brand and specialty tiers. If you owe 25% of $517, that is far more than 25% of $197. When your share is a percentage, a lower negotiated price lowers your bill directly.

It may not change a flat copay

If your plan charges a fixed dollar copay for that tier, your copay can stay the same even though the plan is paying less. The benefit then shows up in the program's overall costs rather than your receipt.

It changes how fast you hit the cap

Your spending counts toward the $2,100 annual Part D out-of-pocket cap in 2026. A cheaper drug means a smaller share each month, which can mean you reach the cap later or not at all, so the year-end picture differs from past years.

It does not change coverage rules

A negotiated price does not force a plan to cover Xarelto, drop prior authorization, or change its tier. Plans still set their own formularies, so check yours before you assume the new price applies to you.

Because tiers and cost-sharing vary so much between plans, the only way to know your real cost is to check Xarelto against each plan's formulary. If you would rather have that done for you, our Find My Medicare Plan service checks your specific drugs against the plans available to you for a flat $99.

Is There a Generic for Xarelto?

Partly, and the detail matters. FDA-approved generic rivaroxaban exists, and CMS has determined there is now bona fide generic competition, which is why Xarelto leaves the negotiation program in 2027. But the launch has been uneven across tablet strengths, and reports conflict on which doses are actually stocked. Since the 15 mg and 20 mg strengths are the common atrial fibrillation doses, ask your pharmacist whether a generic is available at your specific dose.

Does Insurance Cover Xarelto?

Usually, with conditions

Xarelto is covered by Medicare Part D and essentially all commercial plans, usually on a preferred or non-preferred brand tier, sometimes with prior authorization. As generic rivaroxaban becomes more widely stocked, expect plans to prefer it and to move the brand to a worse tier, which is a formulary change rather than a denial.

If you are denied or moved a tier

A denial is not the end, and a tier change at renewal is not either. Your prescriber can submit a letter of medical necessity or a formulary exception, and you have formal appeal rights. See how to appeal an insurance denial and what to do when a plan drops your drug.

How to Pay Less

Ask whether a generic exists at your exact dose

Generic rivaroxaban launched unevenly by strength. "Is there a generic for Xarelto" and "is there a generic of my 20 mg tablet" can have different answers, and only the second one helps you.

On commercial insurance, use the manufacturer copay card

The Janssen savings program can reduce a commercial copay substantially. It cannot be used with Medicare, Medicaid or other federal coverage. On Medicare, Extra Help is the equivalent lever and is worth checking.

On Medicare, check Extra Help and the payment plan

Extra Help (the Low Income Subsidy) sharply reduces Part D costs and its income limits are higher than most people expect. The Medicare Prescription Payment Plan can also spread your Part D costs evenly across the year instead of front-loading them, and you opt in through your plan.

Check the tier before you commit to a plan

The same drug can cost very different amounts across plans in the same ZIP code. During open enrollment, compare Xarelto on each plan's formulary, and remember the plan that was cheapest last year may not be this year.

Push back on a bill you have already received

If you were billed more than you expected, or a claim was processed wrong, CareRoute Bill Defense reviews and disputes medical bills, with no fee unless we save you money.

Not sure which plan covers Xarelto best?

For a flat $99, we research the Medicare plans available to you and check them against your specific drugs and doctors, then hand you a clear comparison. We are independent, sell no insurance, and take no commissions.

Frequently Asked Questions

Is Xarelto or Eliquis cheaper on Medicare?

At the Medicare level Xarelto is lower: $197 for a 30-day supply against $231 for Eliquis, both effective January 1, 2026. That does not settle what you pay, because your copay is set by your own plan's tier for each drug, and the two can sit on different tiers within the same plan. Xarelto also leaves the negotiation program on January 1, 2027 while Eliquis remains in it, so the comparison changes next year. More importantly, these drugs are not interchangeable: Xarelto is once daily, Eliquis twice daily, and the clinical choice belongs with your prescriber. Never switch anticoagulants to save money without medical advice.

Why is Xarelto leaving the Medicare negotiation program?

Medicare can only negotiate the price of a drug with no bona fide generic or biosimilar competition. CMS determined that generic rivaroxaban competition now exists, so Xarelto stops being a selected drug on January 1, 2027. Entresto and Stelara are leaving on the same date for the same reason. The $197 negotiated price therefore applies for 2026 only, after which your plan negotiates with the manufacturer the ordinary way. Generic competition usually produces lower prices than negotiation does, so this is generally good news, but check whether a generic is stocked at your specific tablet strength.

What is Medicare's negotiated price for Xarelto?

Medicare negotiated a maximum fair price of $197 for a 30-day supply of Xarelto, effective January 1, 2026. That is 62% below the $517 list price CMS used as the comparison. Xarelto was one of the first ten drugs in the Medicare Drug Price Negotiation Program, selected because it was among the highest-spending Part D drugs without generic or biosimilar competition at the time. The price applies automatically at the pharmacy for Part D members.

Will the negotiated price lower what I actually pay for Xarelto?

It can, but it is not your new copay. The maximum fair price is what Medicare and your Part D plan pay the pharmacy, not automatically what you are charged. If your plan charges coinsurance, a percentage of the drug price, a lower negotiated price lowers your share directly. If your plan charges a flat copay for that tier, your copay may not change at all. Either way, your total Part D out-of-pocket is capped at $2,100 in 2026, after which covered drugs cost you nothing for the rest of the year.

Does insurance cover Xarelto?

Generally yes. Xarelto is covered by Medicare Part D and most commercial plans, though plans commonly require prior authorization and sometimes step therapy, meaning you try a cheaper option first. The tier it sits on, not whether it is covered, is usually what decides your cost, and the same drug can sit on different tiers in two plans sold in the same ZIP code. Check your plan's formulary for the tier and any restrictions before you fill it.

Related

Sources

  • CMS, Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026 (maximum fair price and list-price comparison)
  • CMS / Medicare.gov (Part D out-of-pocket cap, $2,100 in 2026, and the $615 maximum deductible)
  • FDA Orange Book and Purple Book (approval and substitutability status for rivaroxaban)
  • Janssen and Bayer published list price and patient-support program terms

Prices are national figures for a 30-day supply at a common dose and vary by pharmacy, dose, and plan. List prices are the figures CMS published as its negotiation comparison. This page is educational and is not medical or financial advice: do not start, stop, or switch a prescription on the basis of price without talking to your prescriber. Last updated November 20, 2026.